A single course of rituximab therapy is as effective as the current standard of care regimen of drugs for remission induction and maintenance in patients with ANCA-associated Vasculitis (AAV), Immune Tolerance Network (ITN) researchers have demonstrated. The article is published in the iNew England Journal of Medicine/i. AAV is an autoimmune disease marked by the presence of antibodies that attack neutrophils and cause inflammation of the blood vessels, leading ...
via Medindia Health News
More READ
No comments:
Post a Comment